Skip to content

Production of Larvae Expressing Tyrp2 Mutants, C30S and C61W to Purify Tyrp2 Mutant Proteins


National Eye Institute / National Institute of Health


Announcement/Number:  EE21-004970

Post Date: July 29, 2021

Closing Response Date: August 9, 2021

Proposed Award Date: August 12, 2021

Project Title: Production of larvae expressing Tyrp2 mutants, C30S and C61W to purify Tyrp2 mutant proteins

Contracting Office: National Eye Institute, Building 31, Room 6A52

Contact Point/Contracting Officer/Contract Specialist: Elaine Estrella,

North American Classification System (NAICS) Code (include): 325414

Classification Code:  Biological Product (except Diagnostic) Manufacturing



The research of our lab involves a genotype-to-phenotype study in ocular disease. We approach this task in several ways including experiments with recombinant proteins and their mutant variants. All these experiments require the production of large quantities of pure proteins (>10mg) for biochemical, biophysical, and structural protein characterization with the purpose to use these proteins as potential targets in drug screens. Recently we successfully purified in mg-quantities recombinant human tyrosinase and Tyrp1 intra-melanosomal domains, mutant variants, and de-glycosylated proteins in biologically active form.

Recently we successfully purified the human Tyrp2 intra-melanosomal domain, Tyrp2tr, in larvae. Dopachrome tautomerase Tyrp2 is a protein important for regulating eumelanin and phaeomelanin levels in melanosomes. Tyrp2 catalyzes the conversion of L-dopachrome into 5,6-dihydroxyindole-2-carboxylic acid (DHICA). At present, we are interested to express 2 mutant variants of TYRP2 protein, C30S, and C61W, causing OCA8 disease in humans.

It will be important to understand the mechanism of protein-protein interaction in albinism.  Therefore, we are interested in the in vitro study of the chemical reaction catalyzed by these three proteins, tyrosinase, Tyrp1, Tyrp2, and their mutant variants expressed at a large scale, which will permit us to mimic a chemical reaction occurring in vivo and analyze the products of the chemical reaction by using mass spectrometry and other methods.

The larval system is appropriate because we could easily scale up the protein production and purify protein in the Lab in large quantities using our original purification protocols.




  • Design of Two unique Baculovirus expressing Tyrp2tr human protein with C-terminal
  • Preparation of two Baculovirus expressing Tyrp2tr protein.



Payment will be made 30 days after internal receiving in NIH system.


AWARD TYPE            

Firm Fixed



BLDG 10 RM 5B47



A determination by the Government not to compete this proposed contract acquisition based upon responses to the notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response.

The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed. Information provided will be used to assess tradeoffs and alternatives available for the potential requirement and may lead to the development of a solicitation. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted.

Any solicitation resulting from the analysis of information obtained will be announced to the public in Federal Business Opportunities in accordance with the FAR Part 5. However, responses to this notice will not be considered adequate responses to a solicitation. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any nonproprietary technical information in any resultant solicitation(s).


Closing Statement: This notice is not a request for competitive proposals.  However, interested parties may identify their interest and capability to respond to this notice.  Responses to this notice shall contain sufficient information to establish the interested parties’ bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM)

A determination by the Government not to compete this proposed action based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

All responses must be received by August 09, 2021 and must reference number EE21-004970Responses may be submitted electronically to or hand delivered in person. Fax responses will not be accepted.

“All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency.”

Last updated: July 29, 2021